Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
What Is Arthritis?

09 Jul 08

Arthritis is not just a disease of older people – it can affect people of all ages, including children. It is not clear what causes arthritis and there is no cure at present. However, there is plenty you can do to manage yourcondition and lead a full and active life.
PharmiWeb Editor

New generation anti-TNF drug Cimzia (certolizumab pegol) may offer faster control of RA

17 Jun 08

Cimzia (certolizumab pegol) is the first and so far, only, PEGylated, Fc-Free, anti-tumour necrosis factor (TNF) alpha treatment in development for rheumatoid arthritis. Data presented at the Annual European Rheumatology Congress (EULAR) suggest that, in combination with methotrexate, Cimzia acts fast to significantly suppress disease activity, prevent structural damage to joints, preserve physical function and help patients continue working productively.
Olwen Glynn Owen - Pharmiweb Field reporter

Calling all Medical Journalists, Freelance Editors and Medical Experts

21 May 08

We have an enviable position of being visited by over 150,000 people each month looking for pharmaceutical news and jobs, and we need to satisfy their desire for content.
Mike Wood

Smoking - Why Quit?

21 May 08

It is estimated that one in two smokers will die from a smoking related disease, causing, on average, six to eight years of life lost per smoker. Smokers can also impact the health of those around them, for example their children, through passive smoking.
PharmiWeb editor

Blood Disorders Market Analysis & Forecasts Report to 2013

13 May 08

In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments.
Editor

Anti-Obesity Treatments 2007-2012

09 May 08

“By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, research has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.
Nini Wei- Visiongain Ltd

A Day in the Life of a Medical Sales Representative

06 May 08

The ins and outs of the daily life for Medical Sales Reps.
Philip Miles

The Hygiene Hypothesis

15 Apr 08

Why do some people have allergies and some not? And why has the prevalence of allergic disorders been increasing over the past century, especially in industrialised, developed countries?
Mike Wood

Sleep Disorders Market Analysis 2008-2018

11 Apr 08

Which current or future therapies will drive the sleep disorders market from 2008 to 2018? What is the patient identification rate for each of the therapeutic areas? What is the present state of the disease awareness? What R&D opportunities exist for ‘new comers’? Which key companies are involved in the market?
Justyna Drozdzal

Embarrassed to blow your nose?

01 Apr 08

Forget sweat patches, VPLs and spots…a new survey commissioned by Kleenex® has found that it’s blowing your nose in public that causes us the most embarrassment! The survey of hay fever sufferers reveals that most people prefer a quiet sniff over a good nose blow when out and about. However, allergy specialists warn that the more discreet option actually makes symptoms worse.
Jasmine Richards

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.